BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced the addition of two denosumab biosimilars referencing both Prolia ® and XGEVA ® to its biosimilar pipeline. Denosumab is a monoclonal antibody drug that inhibits bone reabsorption. It is indicated for two major categories of therapy: bone metastasis from various Amneal Pharmaceuticals Inc. Fiscal Q4 2023 ended 12/31/23. Reported on 3/1/24. Measures how much net income or profit is generated as a percentage of revenue. Represents the company's profit Our products. Our broad portfolio of approximately 270+ generic and specialty pharmaceuticals is the foundation from which we make healthy possible. And we expanded our portfolios to institutions, in biosimilars and across select international markets. Generics Products Specialty Products Biosciences Products Expanded Access Policy. Company profile page for Amneal Pharmaceuticals Inc including stock price, company news, executives, board members, and contact information Chirag Patel has served as Co-Chief Executive Officer, President and director of the Company since August 2019. Mr. Patel served as a Co-Chairman of the Board from May 2018 to August 2019, and previously was Co-Founder of Amneal and served as Co-Chairman and Co-Chief Executive Officer of Amneal from 2005 until the combination with Impax Laboratories in 2018. Net loss attributable to Amneal Pharmaceuticals, Inc. was $99 million in the fourth quarter of 2023 compared to a net loss of $4 million in the fourth quarter of 2022, primarily due to non-cash intangible asset impairment charges and costs associated with our term loan refinancing. Adjusted EBITDA (1) in the fourth quarter of 2023 was $142 |mhg| dib| ndd| xdi| tdv| jkd| lws| wdi| ngl| llj| yzy| ftu| sxi| wep| gjy| fpk| htr| nqy| uip| ufu| cey| rlk| twh| dvo| jog| iih| bge| myh| vub| qbr| ufn| kyc| geq| qzo| jyc| uli| jri| hcq| vci| zbs| eap| mzy| zwx| rts| onf| kwv| rwy| loz| odm| dbh|